Investigating the role of CREG1 in managing type 2 diabetes
Official title: Role of CREG1 in metabolic homeostasis
Funded at Rutgers Biomedical and Health Sciences · NIH-11026371 · Data updated 2026-11-12
This study is looking at how a protein called CREG1 affects how insulin works in the body, which is important for people with type 2 diabetes, to help find new ways to improve insulin sensitivity and manage the condition better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | February 16, 2023 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $443,293 |
| NIH project number | 5R01DK135309-03 |
| Project ID | NIH-11026371 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are experiencing insulin resistance or type 2 diabetes.
✕Less likely to help
Patients who do not have type 2 diabetes or insulin resistance may not benefit from this research.
What this research studies
This research focuses on understanding how a protein called CREG1 affects insulin signaling and sensitivity, which are crucial for managing type 2 diabetes mellitus (T2DM). By studying both gain- and loss-of-function in liver cells and specific knockout mice, the researchers aim to uncover how CREG1 influences insulin receptor recycling and insulin secretion. The project will explore the impact of CREG1 on insulin action and its potential role in the development of insulin resistance, particularly in the context of high-fat diets. Patients may benefit from insights that could lead to new therapeutic strategies for T2DM.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve insulin sensitivity and overall management of type 2 diabetes.
How similar studies have gone: Previous research has shown promising results in understanding insulin signaling pathways, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Li, Shaohua — Rutgers Biomedical and Health Sciences
- Study coordinator: Li, Shaohua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.